Skip to NavigationSkip to content

Eli Lilly's Emgality cleared for treatment of migraine in Europe

Published on 20/11/18 at 10:40am

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who have at least four days affected by the condition per month, it has emerged.

The self-administered, once monthly subcutaneous injection was shown to provide superior reduction in monthly migraine headache days (MHD) and an improvement in functioning in three Phase 3 studies of participants with episodic and chronic migraine.

Data generated from these trials showed that Emgality hit all primary endpoints of a statistically significant mean reduction from baseline of monthly MHDs compared to placebo in the first month of treatment and every following month. In the two trials of patients with episodic migraine, 60% of patients achieved at least a 50% reduction on average in MHDs in any given month compared to 38.6% and 36% with placebo, while more than a third of patients achieved a 75% or greater reduction on average.

The approval comes on the heels of a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), issued in September earlier this year.

“Severe migraine is a debilitating disease with limited treatment options,” commented Dr Arash Tahbaz, Senior Medical Director UK and Northern Europe. “This approval marks another major milestone for galcanezumab, and offers the potential for reducing the number and severity of migraine attacks for patients and improving their quality of life.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches